Short answer
SELLAS Life Sciences Group, Inc. (SLS) filed an 8-K current report with the SEC on March 11, 2026 reporting Item 8.01 (Other Events). Total warrant exercise proceeds ~$42.6M since Dec 31, 2025 ($26.5M reported Jan 8 + additional $16.1M since).
SELLAS Life Sciences Group, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Total warrant exercise proceeds ~$42.6M since Dec 31, 2025 ($26.5M reported Jan 8 + additional $16.1M since)
- Share count now 179.5M as of March 11, 2026: significant dilution from warrant exercises
- Cash infusion strengthens balance sheet for a clinical-stage biotech with no product revenue
- Warrant exercise volume signals investor confidence in near-term catalysts (vs. warrants expiring unexercised)
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other SELLAS Life Sciences Group, Inc. 8-K filings
Get the next SLS 8-K as it lands
Follow SLS for push alerts, or ask the research agent what this filing means.